BioRegenx, Inc.
BRGX
$0.008
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 460.50K | 596.00K | 734.00K | 549.50K | 678.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 460.50K | 596.00K | 734.00K | 549.50K | 678.00K |
| Cost of Revenue | 137.80K | 114.40K | 264.20K | 165.40K | 300.00K |
| Gross Profit | 322.70K | 481.60K | 469.90K | 384.20K | 378.00K |
| SG&A Expenses | 1.86M | 246.90K | 947.60K | 2.97M | 589.60K |
| Depreciation & Amortization | 562.10K | 562.10K | 562.10K | 497.80K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.56M | 923.30K | 1.77M | 3.63M | 889.60K |
| Operating Income | -2.10M | -327.30K | -1.04M | -3.08M | -211.60K |
| Income Before Tax | -18.40M | -394.90K | -1.11M | -3.15M | -256.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.40M | -394.90K | -1.11M | -3.15M | -256.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.40M | -394.90K | -1.11M | -3.15M | -256.70K |
| EBIT | -2.10M | -327.30K | -1.04M | -3.08M | -211.60K |
| EBITDA | -1.53M | 247.20K | -169.60K | -2.88M | -210.40K |
| EPS Basic | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 971.71M | 956.53M | 956.53M | 956.53M | 696.85M |
| Average Diluted Shares Outstanding | 971.71M | 956.53M | 956.53M | 956.53M | 696.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |